Key Points
- Major shareholder Bioventures 2014 L.P. Mpm has been selling repeatedly in late Nov–Dec (including 60,733 shares on Nov 26), reducing its stake by 1.18% to 5,065,037 shares.
- Shares fell about 8.3%, opening at $0.92; the company has a market cap of roughly $44.5 million, a 52-week range of $0.60–$2.38, and 50/200-day moving averages of $1.46/$1.34.
- Analyst sentiment is a "Moderate Buy" with an average target of $7.75 despite negative EPS forecasts (FY EPS forecast -1.56) and a recent quarter EPS of ($0.36) that slightly beat expectations.
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 13,014 shares of the stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $0.99, for a total transaction of $12,883.86. Following the completion of the transaction, the director directly owned 3,235,559 shares in the company, valued at $3,203,203.41. The trade was a 0.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Luke Evnin also recently made the following trade(s):
- On Monday, December 1st, Luke Evnin sold 39,096 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total transaction of $36,750.24.
- On Wednesday, November 26th, Luke Evnin sold 38,978 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total transaction of $38,198.44.
- On Tuesday, November 25th, Luke Evnin sold 27,297 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.92, for a total transaction of $25,113.24.
- On Monday, November 24th, Luke Evnin sold 56,992 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total value of $55,852.16.
- On Friday, November 21st, Luke Evnin sold 41,287 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.83, for a total value of $34,268.21.
- On Thursday, November 20th, Luke Evnin sold 26,411 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.89, for a total value of $23,505.79.
- On Wednesday, November 19th, Luke Evnin sold 42,566 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total value of $40,012.04.
- On Tuesday, November 18th, Luke Evnin sold 33,776 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.93, for a total value of $31,411.68.
- On Monday, November 17th, Luke Evnin sold 36,621 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.95, for a total value of $34,789.95.
- On Friday, November 14th, Luke Evnin sold 39,560 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.93, for a total value of $36,790.80.
Werewolf Therapeutics Trading Down 8.3%
Shares of Werewolf Therapeutics stock opened at $0.92 on Tuesday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. The firm has a 50-day moving average of $1.46 and a 200-day moving average of $1.34. Werewolf Therapeutics, Inc. has a 52-week low of $0.60 and a 52-week high of $2.38. The stock has a market cap of $44.50 million, a PE ratio of -0.57 and a beta of 0.72.
Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.39) by $0.03. As a group, sell-side analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on the stock. Zacks Research downgraded shares of Werewolf Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, November 21st. Citigroup reissued a "market outperform" rating on shares of Werewolf Therapeutics in a research report on Wednesday, November 12th. Bank of America dropped their price objective on Werewolf Therapeutics from $8.00 to $7.00 and set a "buy" rating for the company in a report on Tuesday, November 18th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Finally, JMP Securities reduced their target price on Werewolf Therapeutics from $4.00 to $3.00 and set a "market outperform" rating on the stock in a report on Thursday, August 21st. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $7.75.
Get Our Latest Stock Analysis on Werewolf Therapeutics
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the company. Susquehanna International Group LLP lifted its stake in Werewolf Therapeutics by 16.9% during the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company's stock worth $183,000 after purchasing an additional 13,439 shares during the last quarter. MPM Bioimpact LLC increased its stake in shares of Werewolf Therapeutics by 0.9% in the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company's stock valued at $2,341,000 after purchasing an additional 20,799 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Werewolf Therapeutics by 33.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company's stock worth $93,000 after buying an additional 23,852 shares in the last quarter. MPM Asset Management LLC raised its holdings in shares of Werewolf Therapeutics by 0.6% during the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company's stock worth $4,189,000 after buying an additional 25,688 shares in the last quarter. Finally, Quadrature Capital Ltd bought a new stake in shares of Werewolf Therapeutics during the 2nd quarter worth $28,000. 64.84% of the stock is currently owned by institutional investors and hedge funds.
About Werewolf Therapeutics
(
Get Free Report)
Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
